Literature DB >> 34599091

Highly active engineered IgG3 antibodies against SARS-CoV-2.

Somanath Kallolimath1, Lin Sun1, Roman Palt1, Karin Stiasny2, Patrick Mayrhofer3, Clemens Gruber4, Benjamin Kogelmann1, Qiang Chen5, Herta Steinkellner6.   

Abstract

Monoclonal antibodies (mAbs) that efficiently neutralize SARS-CoV-2 have been developed at an unprecedented speed. Notwithstanding, there is a vague understanding of the various Ab functions induced beyond antigen binding by the heavy-chain constant domain. To explore the diverse roles of Abs in SARS-CoV-2 immunity, we expressed a SARS-CoV-2 spike protein (SP) binding mAb (H4) in the four IgG subclasses present in human serum (IgG1-4) using glyco-engineered Nicotiana benthamiana plants. All four subclasses, carrying the identical antigen-binding site, were fully assembled in planta and exhibited a largely homogeneous xylose- and fucose-free glycosylation profile. The Ab variants ligated to the SP with an up to fivefold increased binding activity of IgG3. Furthermore, all H4 subtypes were able to neutralize SARS-CoV-2. However, H4-IgG3 exhibited an up to 50-fold superior neutralization potency compared with the other subclasses. Our data point to a strong protective effect of IgG3 Abs in SARS-CoV-2 infection and suggest that superior neutralization might be a consequence of cross-linking the SP on the viral surface. This should be considered in therapy and vaccine development. In addition, we underscore the versatile use of plants for the rapid expression of complex proteins in emergency cases.
Copyright © 2021 the Author(s). Published by PNAS.

Entities:  

Keywords:  SARS-CoV-2; antibodies; engineered IgG3; plant-based expression; virus neutralization

Mesh:

Substances:

Year:  2021        PMID: 34599091      PMCID: PMC8545452          DOI: 10.1073/pnas.2107249118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


Pre- and postexposure immunotherapies with neutralizing antibodies (nAbs) are presently being explored for the prevention and treatment of COVID-19. This has, at an unprecedented speed, led to the isolation of mAbs that efficiently neutralize SARS-CoV-2 (e.g., H4) (1). These mAbs, mainly directed against spike protein (SP) on the virion`s surface, are predominantly of the IgG1 subtype. However, a strong prevalence of other subclasses (like IgG3 and IgG4) was observed in the sera of COVID-19 patients (2), indicating a protective effect during the viral infection. While the role of IgG1 is intensively investigated, data on the functional impact of the other IgG subclasses, discriminated mainly by diverse Fc domains, are rare. Notably, the first SARS-CoV-2 studies on distinct IgG-Fc functional profiling point to enhancement of disease (3), in line with data from SARS-CoV experiments (4). These data underscore the need for a better understanding of the molecular properties of SARS-CoV-2 Ab variants prior to application in therapy or prophylaxis. To further explore the role of Ab domains beyond antigen-binding in SARS-CoV-2 immunity, we focused on the expression and functional analyses of a neutralizing mAb with identical variable domains but different constant heavy chains (HCs), representing all four IgG subclasses present in human serum (IgG1-4).

Results

Production of Recombinant Monoclonal H4-IgG Subclasses.

H4 SARS-CoV-2 neutralizing monoclonal IgG1 antibody that binds to an epitope at the receptor-binding domain of the SP (1) served as a template in this study. Four plant expression constructs with identical variable regions but different HC domains, representing human subclasses IgG1-4, were generated (H4-IgGHC1-4) (). The IgG3 isotype refers to allotype G3m5, containing a 62-amino-acid hinge domain. For light-chain expression, a single construct carrying the variable region of H4 and κ-light chain constant (κ-LC) domain was used for all subclasses (H4-IgGLC). Respective vectors of H4-IgGHC1-4 and H4-IgGLC were coexpressed in Nicotiana benthamiana glycosylation mutant ΔXTFT by agroinfiltration (5, 6) and purified at 4 d postinfiltration by protein A–based affinity and subsequent size-exclusion chromatography. SDS/PAGE analysis of purified mAbs revealed the correct expression, assembly, and high purity of all four subclasses (Fig. 1).
Fig. 1.

Biochemical characterization and antigen-binding activities of recombinant H4-IgG1-4 produced in ΔXTFT. (A) Purified H4-IgG1-4 separated by reducing and nonreducing SDS/PAGE (Coomassie brilliant blue stained), 4 µg protein was loaded at each lane. (B) LC-ESI-MS/MS–derived glycosylation profiles of purified H4-IgG1-4. Bars represent the relative abundance (%) of glycoforms present at the conserved Fc glycosite. (C) ELISA-binding activity EC50 values in nanomoles of purified H4-IgG1-4 to SP using antibodies against κ-LC for detection.

Biochemical characterization and antigen-binding activities of recombinant H4-IgG1-4 produced in ΔXTFT. (A) Purified H4-IgG1-4 separated by reducing and nonreducing SDS/PAGE (Coomassie brilliant blue stained), 4 µg protein was loaded at each lane. (B) LC-ESI-MS/MS–derived glycosylation profiles of purified H4-IgG1-4. Bars represent the relative abundance (%) of glycoforms present at the conserved Fc glycosite. (C) ELISA-binding activity EC50 values in nanomoles of purified H4-IgG1-4 to SP using antibodies against κ-LC for detection.

Glycosylation Status of Plant-Derived H4-IgG Subclasses.

It is well known that the conserved Fc glycosylation at position N297 plays a vital role in Fcγ receptor (FcγR) interactions and effector function. In line, recent results demonstrate glycosylation-dependent functional effects during COVID-19 (7). Thus, we aimed at the production of mAbs with a targeted glycosylation profile. Liquid chromatography–electrospray ionization–tandem mass spectrometry (LC-ESI-MS/MS) () of H4-IgG1-4 revealed a largely homogeneous Fc glycosylation profile, with ∼90% GnGn structures (i.e., core xylose and fucose-free N-glycans) (Fig. 1).

Antigen-Binding and Neutralization Potency of H4-IgG Subclasses.

Antigen-binding properties of H4-IgG1-4 were determined by ELISA using Chinese hamster ovary–produced SARS-CoV-2 SP. The following binding activities, expressed by EC50 values, were obtained: IgG2 < IgG1 = IgG4 < IgG3 (EC50 1.95, 1.08, 1.18, and 0.4 nM, respectively) with an up to fivefold increased binding of IgG3 compared to the lowest binder, IgG2 (Fig. 1). To further determine functional activities of Ab subclasses, Vero cell–based SARS-CoV-2 neutralization (NT) assays were performed, as described previously (8) (). IgG1, IgG2, and IgG4 exhibited similar NT potencies (NT100 295.88, 296.49, and 222.36 nM, respectively) (Table 1). However, IgG3 displayed an up to 50-fold increased activity (NT100 5.91 nM) (Table 1) in comparison with the other subclasses. Our results point to an important role of HC domains that are not directly involved in antigen binding.
Table 1.

SARS-CoV-2 NT activities (NT100 values) of H4-IgG subclasses

Ab subtypeNT100 (nM)
H4-IgG1295.88
H4-IgG2296.49
H4-IgG35.91
H4-IgG4222.36
SARS-CoV-2 NT activities (NT100 values) of H4-IgG subclasses

Discussion

While major differences in IgG subtype prevalence in human sera during and after viral infections compared to healthy individuals are frequently observed, the consequences thereof are not well understood. Here we performed a side-by-side comparison of a SARS-CoV-2 neutralizing mAb with identical antigen-binding domains but four different HCs. Our results demonstrate substantially increased NT activities of IgG3 compared to the other three subclasses, despite relative modest variations in antigen binding. Major differences of IgG3 compared to the other IgG subclasses are the long O-glycosylated hinge region and single point mutations in the Fc domain that enable, for example, high-affinity interaction with activating FcγRs. Such characteristics make IgG3 a uniquely potent immunoglobulin, with the potential for triggering effector functions and enhanced viral NT (9). Since we used Vero cells that do not carry FcγR in our studies, superior SARS-CoV-2 NT induced by Fc-mediated effector activities can be excluded. More likely, our data suggest that the unusual hinge region of IgG3 is a key factor that mediates altered activities. Indeed, previous studies, particularly in HIV settings, report a significant impact of the hinge region on the Ab’s functional activities (10). It has been suggested that augmented Ab-based NT potency toward HIV is driven by “intratrimeric cross-linking” of the two Fab arms, thus increasing the overall avidity of the spike–Ab interaction (11, 12). Our data are in line with such studies and indicate that enhanced SARS-CoV-2 NT is a consequence of cross-linking SP on the viral surface, induced by the unique structural features of IgG3. Also in accordance with HIV data (11), we hypothesize that cross-linking lowers the concentration of Abs required for NT and low spike densities facilitate Ab evasion. Interestingly, the SP copy number per SARS-CoV-2 virion is comparable with HIV, but 5 to 10 times less than that of other enveloped viruses, such as the influenza virus (13, 14). Notably, epitope-specific induction of neutralizing IgG3 Abs has been reported (e.g., HIV, Chikungunya virus) (9). This is an additional factor that cannot be excluded in our studies. In addition, we show the expression of Ab variants with a single dominant N-glycan species (i.e., GnGn or G0). This glycan form, known to confer proinflammatory activities on Abs, is detected only in minor amounts in human-derived Abs. Here, we do not expect functional alterations due to this modification; however, fucose-free SARS-CoV-2 Abs may exhibit increased in vivo activities. This needs to be proven. In addition, the conserved core GnGn structures (5) simplify further engineering to elucidate so far potentially unknown glycosylation-dependent activities of SARS-CoV-2 antibodies, as suggested recently (7). Collectively, our results deliver insights into SARS-CoV-2 immunology and should perchance be considered for therapy or passive SARS-CoV-2 protection.

Materials and Methods

In planta expression of IgG subtypes was accomplished by agroinfiltration of respective DNA constructs. Subsequently, affinity- and size exclusion chromatography–purified mAbs were subjected to ELISA antigen-binding assays and NT activity was measured by a Vero cell–based SARS-CoV-2 infection assay, as described recently (8). Materials and methods are detailed in .
  14 in total

1.  Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure.

Authors:  Richard Strasser; Johannes Stadlmann; Matthias Schähs; Gabriela Stiegler; Heribert Quendler; Lukas Mach; Josef Glössl; Koen Weterings; Martin Pabst; Herta Steinkellner
Journal:  Plant Biotechnol J       Date:  2008-03-13       Impact factor: 9.803

2.  Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.

Authors:  Li Liu; Qiang Wei; Qingqing Lin; Jun Fang; Haibo Wang; Hauyee Kwok; Hangying Tang; Kenji Nishiura; Jie Peng; Zhiwu Tan; Tongjin Wu; Ka-Wai Cheung; Kwok-Hung Chan; Xavier Alvarez; Chuan Qin; Andrew Lackner; Stanley Perlman; Kwok-Yung Yuen; Zhiwei Chen
Journal:  JCI Insight       Date:  2019-02-21

3.  A serological assay to detect SARS-CoV-2 seroconversion in humans.

Authors:  Fatima Amanat; Daniel Stadlbauer; Shirin Strohmeier; Thi H O Nguyen; Veronika Chromikova; Meagan McMahon; Kaijun Jiang; Guha Asthagiri Arunkumar; Denise Jurczyszak; Jose Polanco; Maria Bermudez-Gonzalez; Giulio Kleiner; Teresa Aydillo; Lisa Miorin; Daniel S Fierer; Luz Amarilis Lugo; Erna Milunka Kojic; Jonathan Stoever; Sean T H Liu; Charlotte Cunningham-Rundles; Philip L Felgner; Thomas Moran; Adolfo García-Sastre; Daniel Caplivski; Allen C Cheng; Katherine Kedzierska; Olli Vapalahti; Jussi M Hepojoki; Viviana Simon; Florian Krammer
Journal:  Nat Med       Date:  2020-05-12       Impact factor: 53.440

4.  Structures and distributions of SARS-CoV-2 spike proteins on intact virions.

Authors:  Zunlong Ke; Joaquin Oton; Kun Qu; Mirko Cortese; Vojtech Zila; Lesley McKeane; Takanori Nakane; Jasenko Zivanov; Christopher J Neufeldt; Berati Cerikan; John M Lu; Julia Peukes; Xiaoli Xiong; Hans-Georg Kräusslich; Sjors H W Scheres; Ralf Bartenschlager; John A G Briggs
Journal:  Nature       Date:  2020-08-17       Impact factor: 49.962

5.  Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.

Authors:  Stylianos Bournazos; Anna Gazumyan; Michael S Seaman; Michel C Nussenzweig; Jeffrey V Ravetch
Journal:  Cell       Date:  2016-06-16       Impact factor: 41.582

6.  A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.

Authors:  Yan Wu; Feiran Wang; Chenguang Shen; Weiyu Peng; Delin Li; Cheng Zhao; Zhaohui Li; Shihua Li; Yuhai Bi; Yang Yang; Yuhuan Gong; Haixia Xiao; Zheng Fan; Shuguang Tan; Guizhen Wu; Wenjie Tan; Xuancheng Lu; Changfa Fan; Qihui Wang; Yingxia Liu; Chen Zhang; Jianxun Qi; George Fu Gao; Feng Gao; Lei Liu
Journal:  Science       Date:  2020-05-13       Impact factor: 47.728

7.  Molecular Architecture of the SARS-CoV-2 Virus.

Authors:  Hangping Yao; Yutong Song; Yong Chen; Nanping Wu; Jialu Xu; Chujie Sun; Jiaxing Zhang; Tianhao Weng; Zheyuan Zhang; Zhigang Wu; Linfang Cheng; Danrong Shi; Xiangyun Lu; Jianlin Lei; Max Crispin; Yigong Shi; Lanjuan Li; Sai Li
Journal:  Cell       Date:  2020-09-06       Impact factor: 41.582

8.  Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.

Authors:  Caroline Atyeo; Matthew D Slein; Stephanie Fischinger; John Burke; Alexandra Schäfer; Sarah R Leist; Natalia A Kuzmina; Chad Mire; Anna Honko; Rebecca Johnson; Nadia Storm; Matthew Bernett; Pei Tong; Teng Zuo; Junrui Lin; Adam Zuiani; Caitlyn Linde; Todd Suscovich; Duane R Wesemann; Anthony Griffiths; John R Desjarlais; Boris D Juelg; Jaap Goudsmit; Alexander Bukreyev; Ralph Baric; Galit Alter
Journal:  JCI Insight       Date:  2021-01-11

9.  Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity.

Authors:  Mads Delbo Larsen; Erik L de Graaf; Myrthe E Sonneveld; H Rosina Plomp; Jan Nouta; Willianne Hoepel; Hung-Jen Chen; Federica Linty; Remco Visser; Maximilian Brinkhaus; Tonći Šuštić; Steven W de Taeye; Arthur E H Bentlage; Suvi Toivonen; Carolien A M Koeleman; Susanna Sainio; Neeltje A Kootstra; Philip J M Brouwer; Chiara Elisabeth Geyer; Ninotska I L Derksen; Gertjan Wolbink; Menno de Winther; Rogier W Sanders; Marit J van Gils; Sanne de Bruin; Alexander P J Vlaar; Theo Rispens; Jeroen den Dunnen; Hans L Zaaijer; Manfred Wuhrer; C Ellen van der Schoot; Gestur Vidarsson
Journal:  Science       Date:  2020-12-23       Impact factor: 47.728

View more
  16 in total

Review 1.  Development of plant-made monoclonal antibodies against viral infections.

Authors:  Qiang Chen
Journal:  Curr Opin Virol       Date:  2021-12-18       Impact factor: 7.090

2.  Editorial: Complement and COVID-19 Disease.

Authors:  Zoltán Prohászka; Nicolas S Merle
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

3.  IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools.

Authors:  Christina Kober; Sandro Manni; Svenja Wolff; Thomas Barnes; Shatanik Mukherjee; Thomas Vogel; Lea Hoenig; Peter Vogel; Aaron Hahn; Michaela Gerlach; Martin Vey; Eleonora Widmer; Björn Keiner; Patrick Schuetz; Nathan Roth; Uwe Kalina
Journal:  PLoS One       Date:  2022-01-04       Impact factor: 3.240

4.  Validation and performance of a multiplex serology assay to quantify antibody responses following SARS-CoV-2 infection or vaccination.

Authors:  Deidre Wilkins; Anastasia A Aksyuk; Alexey Ruzin; Kevin M Tuffy; Tina Green; Rebecca Greway; Brittany Fikes; Cyrille J Bonhomme; Mark T Esser; Elizabeth J Kelly
Journal:  Clin Transl Immunology       Date:  2022-04-26

Review 5.  Overview of Neutralizing Antibodies and Their Potential in COVID-19.

Authors:  José Javier Morales-Núñez; José Francisco Muñoz-Valle; Paola Carolina Torres-Hernández; Jorge Hernández-Bello
Journal:  Vaccines (Basel)       Date:  2021-11-23

6.  Functional Trimeric SARS-CoV-2 Envelope Protein Expressed in Stable CHO Cells.

Authors:  Patrick Mayrhofer; Monika Hunjadi; Renate Kunert
Journal:  Front Bioeng Biotechnol       Date:  2021-12-17

7.  Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG.

Authors:  Lin Sun; Somanath Kallolimath; Roman Palt; Karin Stiasny; Patrick Mayrhofer; Daniel Maresch; Lukas Eidenberger; Herta Steinkellner
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-02       Impact factor: 12.779

Review 8.  Improving Protein Quantity and Quality-The Next Level of Plant Molecular Farming.

Authors:  Hai Liu; Michael P Timko
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

9.  Reply to Pandey: Possible functional impact of IgG3 allotype constant region.

Authors:  Somanath Kallolimath; Falk Nimmerjahn; Herta Steinkellner
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-08       Impact factor: 11.205

10.  IgG3 constant region GM (γ marker) allotypes could influence the neutralizing potency of anti-SARS-CoV-2 monoclonal antibodies.

Authors:  Janardan P Pandey
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.